- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04531878
BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases
February 7, 2023 updated by: Children's Hospital of Fudan University
Jian-She Wang of Children's Hospital of Fudan University
The purpose of the study is to improve the prognosis of inhereditary cholestasis caused by ABCB11 gene mutations by using BSEP function rescue drugs
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Bile acids function as detergents to aid digestion and as signaling molecules to regulate gene expression and metabolism.
They are synthesized from cholesterol in the liver, secreted into bile and re -turned from chyme to liver in portal- vein blood 6-10 times per day (enterohepatic circulation.
Enterohepatic circulation of bile acids involves more than 20 transporters among which bile salt export pump (BSEP), encoded by ABCB11 plays a key role.
BSEP medi-ates the secretion of bile acids across the canalicular membrane of hepatocytes into bile to provide the osmotic pressure for bile flow.
Mutations in ABCB11 can cause absence or dysfunction of BSEP leading to cholestasis.
Bile acid accumulation in hepatocytes caused by BSEP dysfunction is associated with a range of liver dis-eases, ranging from transient neonatal cholestasis to fatal progressive familial intrahepatic cholestasis (PFIC), with jaundice, growth retardation, cirrhosis, liver failure and death.
Our current indicates that more than 70% patents with ABCB11 mutations need liver-transplantation or dead during follow-up.
In recent years, some targeted drugs including 4-phenylbutyrate(for patients with BSEP trafficking abnormal), ivacaftor(for patients with abnormal BSEP transport function), and gentamicin (for patients with none sense mutations) have emerged make it possible for individual targeted therapy possible.
Study Type
Interventional
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jian-She Wang, Ph.D
- Phone Number: 86-02164931171
- Email: jshwang@shmu.edu.cn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 18 years (ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- with signed informed consent form from the guardian, and the patient if applicable.
- aged from 2 month to 18 years old.
- with cholestatic disease caused by ABCB11 biallelic mutation.
- Long-term residence in China.
Exclusion Criteria:
- Currently receiving or previously received experimental drugs.
- The child is already in the stage of liver failure, or in unstable state that are not suitable for drug treatment according to the researcher's judgment: serious complications such as bleeding tendency and skin rash.
- accompany with other chronic liver disease (viral hepatitis B and C, autoimmune hepatitis, wilson disease, cystic fibrosis, primary biliary cirrhosis, biliary atresia, sclerosing cholangitis, bile acid synthesis defects, and infections, cholestasis caused by space-occupying and other reasons).
- Suffered from congenital TORCHES infection, including toxoplasma gondii, rubella virus, cytomegalovirus, herpes simplex virus, EB virus, syphilis, HIV, etc.
- With any other major medical conditions that may affect drug absorption, metabolism, or excretion based on the researcher's judgment.
- Known or suspected hypersensitivity to any experimental drugs or their indigents.
- Patients with alcohol or drug dependence.
- In receiving any investigational drugs or within 60 days before enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: BSEP trafficking abnormal group
Patients with ABCB11 missense mutations that were speculated to affect the BSEP trafficking
|
4-phenylbutyrate therapy will be started at a daily dose of 200 mg kg/d divided in 2 oral doses of sodium phenylbutyrate (AMMONAPS, Swedish Orphan Inter AB).
In order to get the best effect, the dose will be increased up to a maximum of 500 mg kg/d.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Native liver survive time
Time Frame: During follow-up (about 3 years)
|
Time of patient survived with native liver will be accessed.
|
During follow-up (about 3 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ALT(Alanine Aminotransferase)
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
ALT would be measured.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
DB(direct bilirubin) levels
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
DB would be measured.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
TB(total bilirubin)
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
TB would be measured.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
AST(Aspartate Aminotransferase)
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
AST would be measured.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
Weight
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
The weight of the patients.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
Length
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
The length of the patients
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
Itching relief
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.The itching score level will be accessed using a score ranged from 0 to 10.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
Liver pathological staging
Time Frame: day 90, 180
|
It is a repeated measurement variable.Liver pathological staging will be accessed using the Batts-Ludwig system.
|
day 90, 180
|
Coagulation function
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.The INR(international normalized ratio)/PT(prothrombin time) levels will be followed if with coagulation function abnormal.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
Hypoglycemia
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.The glucose wil be followed.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
Hypo25-hydroxyvitamin Demia
Time Frame: at day 0, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
Hypo25-hydroxyvitamin D levels will be followed.
|
at day 0, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
The bile acid profiling
Time Frame: at day 30, 60, 90, 180, 360, 720 and 1080
|
It is a repeated measurement variable.
The bile acid profiling will be checked during follow-up.
|
at day 30, 60, 90, 180, 360, 720 and 1080
|
Hypoproteinemia
Time Frame: at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
It is a repeated measurement variable.
The albumin wil be followed.
|
at day 0, 7, 14, 28, 56, 90, 120, 180, 240, 300, 360, 540, 720 and 1080
|
Adverse events
Time Frame: During follow-up (about 3 years)
|
It is a binary variable(1/0).
If any adverse events including bleeding, fractures, tumors, and hepatic encephalopathy happended during the follow-up, the variable would be setted into "1".
The incidence of each adverse events will also be calculated.
|
During follow-up (about 3 years)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
February 8, 2023
Primary Completion (ACTUAL)
February 8, 2023
Study Completion (ACTUAL)
February 8, 2023
Study Registration Dates
First Submitted
August 26, 2020
First Submitted That Met QC Criteria
August 26, 2020
First Posted (ACTUAL)
August 31, 2020
Study Record Updates
Last Update Posted (ESTIMATE)
February 9, 2023
Last Update Submitted That Met QC Criteria
February 7, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BSEP_FudanEK_001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cholestasis, Intrahepatic
-
Mirum Pharmaceuticals, Inc.CompletedProgressive Familial Intrahepatic Cholestasis (PFIC)Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
-
TakedaActive, not recruitingProgressive Familial Intrahepatic Cholestasis (PFIC)Japan
-
Mirum Pharmaceuticals, Inc.Active, not recruitingProgressive Familial Intrahepatic Cholestasis (PFIC)United States, Argentina, France, Singapore, United Kingdom, Belgium, Turkey, Austria, Brazil, Canada, Colombia, Germany, Italy, Lebanon, Mexico, Poland
-
Mirum Pharmaceuticals, Inc.WithdrawnProgressive Familial Intrahepatic Cholestasis (PFIC)
-
Institute of Liver and Biliary Sciences, IndiaKEM Hospital Research Centre; Apollo Hospital, New Delhi, India; Jaslok Hospital... and other collaboratorsRecruitingProgressive Familial Intrahepatic CholestasisIndia
-
University Medical Center GroningenEnrolling by invitationProgressive Familial Intrahepatic CholestasisNetherlands
-
AlbireoActive, not recruitingProgressive Familial Intrahepatic CholestasisUnited States, Spain, Netherlands, United Kingdom, Turkey, Canada, Italy, Germany, France, Israel, Australia, Belgium, Poland, Saudi Arabia, Sweden
-
AlbireoApproved for marketingProgressive Familial Intrahepatic CholestasisUnited States
-
National Liver Institute, EgyptUnknownProgressive Familial Intrahepatic CholestasisEgypt
-
Turku University HospitalCompletedPregnancy | Intrahepatic CholestasisFinland
Clinical Trials on 4-Phenylbutyrate
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States, Canada
-
National Cancer Institute (NCI)CompletedBrain Neoplasms | NeuroblastomaUnited States
-
National Cancer Institute (NCI)CompletedBrain TumorUnited States
-
WestatNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedSpinal Muscular Atrophy Type IUnited States
-
WestatNational Institute of Neurological Disorders and Stroke (NINDS)TerminatedSpinal Muscular Atrophy Type II | Spinal Muscular Atrophy Type IIIUnited States
-
Jerry Vockley, MD, PhDAcer Therapeutics Inc.RecruitingMedium-chain Acyl-CoA Dehydrogenase DeficiencyUnited States
-
US Department of Veterans AffairsMuscular Dystrophy AssociationCompletedAmyotrophic Lateral SclerosisUnited States
-
Horizon Pharma Ireland, Ltd., Dublin IrelandCompletedUrea Cycle DisordersUnited States, Canada
-
University of NottinghamRecruitingObese Non DiabeticUnited Kingdom
-
University of RochesterJohns Hopkins University; Massachusetts General Hospital; University of California... and other collaboratorsCompletedHuntington's DiseaseUnited States